Penetration of ampicillin and sulbactam in the lower airways during respiratory infections
- PMID: 2393293
- PMCID: PMC171737
- DOI: 10.1128/AAC.34.6.958
Penetration of ampicillin and sulbactam in the lower airways during respiratory infections
Abstract
We studied the penetration of ampicillin-sulbactam in the alveolar lining fluid (ALF) of eight patients after intravenous administration of 2,000 mg of ampicillin and 1,000 mg of sulbactam three times daily over 30 min. Bronchoalveolar lavage was performed on day 3, 30 min after the end of the morning drug administration. The mean penetration ratios (i.e., the ratios of the concentrations in ALF versus those in serum) were 53% (standard error, 12%) and 61% (standard error 31%) for ampicillin and sulbactam, respectively. The concentration ratio of ampicillin versus sulbactam in serum was not significantly different from that in ALF. From a pharmacokinetic point of view, ampicillin-sulbactam is a good choice for treatment of infectious exacerbation of chronic obstructive pulmonary disease and community-acquired bacterial pneumonia, since the concentrations of both drugs in ALF exceed the MICs for the respiratory pathogens responsible.
Similar articles
-
Concentrations of sulbactam/ampicillin in serum and lung tissue.Infection. 1990 Sep-Oct;18(5):307-9. doi: 10.1007/BF01647016. Infection. 1990. PMID: 2276827
-
Concentrations of ampicillin and sulbactam in serum and in various compartments of the respiratory tract of patients.Infection. 1994 Mar-Apr;22(2):149-51. doi: 10.1007/BF01739027. Infection. 1994. PMID: 8070929
-
Ampicillin/sulbactam in lower respiratory tract infections: a review.Clin Ther. 1991 Nov-Dec;13(6):714-26. Clin Ther. 1991. PMID: 1790546 Review.
-
Use of ampicillin/sulbactam and sultamicillin in pediatric infections: a re-evaluation.J Int Med Res. 2001 Jul-Aug;29(4):257-69. doi: 10.1177/147323000102900401. J Int Med Res. 2001. PMID: 11675898 Review.
-
[Clinical evaluation of sulbactam/ampicillin in the pediatric infections].Jpn J Antibiot. 1989 Mar;42(3):612-22. Jpn J Antibiot. 1989. PMID: 2746845 Japanese.
Cited by
-
Pharmacokinetic/pharmacodynamic analysis of sulbactam against Acinetobacter baumannii pneumonia: establishing in vivo efficacy targets in the epithelial lining fluid.JAC Antimicrob Resist. 2024 Dec 20;6(6):dlae203. doi: 10.1093/jacamr/dlae203. eCollection 2024 Dec. JAC Antimicrob Resist. 2024. PMID: 39712636 Free PMC article.
-
Optimizing Treatment for Carbapenem-Resistant Acinetobacter baumannii Complex Infections: A Review of Current Evidence.Infect Chemother. 2024 Jun;56(2):171-187. doi: 10.3947/ic.2024.0055. Infect Chemother. 2024. PMID: 38960737 Free PMC article. Review.
-
Use of a predictor panel to evaluate susceptibility testing methods for ampicillin-sulbactam.Antimicrob Agents Chemother. 1993 Feb;37(2):251-9. doi: 10.1128/AAC.37.2.251. Antimicrob Agents Chemother. 1993. PMID: 8452355 Free PMC article.
-
Antibiotic prophylaxis of early onset pneumonia in critically ill comatose patients. A randomized study.Intensive Care Med. 2005 Apr;31(4):510-6. doi: 10.1007/s00134-005-2585-5. Epub 2005 Mar 8. Intensive Care Med. 2005. PMID: 15754197 Clinical Trial.
-
Pulmonary Pharmacokinetic and Pharmacodynamic Evaluation of Ampicillin/Sulbactam Regimens for Pneumonia Caused by Various Bacteria, including Acinetobacter baumannii.Antibiotics (Basel). 2023 Feb 2;12(2):303. doi: 10.3390/antibiotics12020303. Antibiotics (Basel). 2023. PMID: 36830214 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources